GT Biopharma Inc (GTBP) - Net Assets
Based on the latest financial reports, GT Biopharma Inc (GTBP) has net assets worth $5.79 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($8.11 Million) and total liabilities ($2.32 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check GT Biopharma Inc (GTBP) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $5.79 Million |
| % of Total Assets | 71.39% |
| Annual Growth Rate | 1.5% |
| 5-Year Change | -73.59% |
| 10-Year Change | N/A |
| Growth Volatility | 194.03 |
GT Biopharma Inc - Net Assets Trend (1983–2025)
This chart illustrates how GT Biopharma Inc's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of GT Biopharma Inc for the complete picture of this company's asset base.
Annual Net Assets for GT Biopharma Inc (1983–2025)
The table below shows the annual net assets of GT Biopharma Inc from 1983 to 2025. For live valuation and market cap data, see GTBP company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $5.79 Million | +446.53% |
| 2024-12-31 | $-1.67 Million | -122.34% |
| 2023-12-31 | $7.48 Million | -36.29% |
| 2022-12-31 | $11.73 Million | -46.44% |
| 2021-12-31 | $21.91 Million | +174.44% |
| 2020-12-31 | $-29.43 Million | -52.42% |
| 2019-12-31 | $-19.31 Million | -269.83% |
| 2018-12-31 | $11.37 Million | -95.48% |
| 2017-12-31 | $251.69 Million | +1430.00% |
| 2016-12-31 | $-18.92 Million | +62.58% |
| 2015-12-31 | $-50.57 Million | -70.99% |
| 2014-12-31 | $-29.57 Million | -366.91% |
| 2013-12-31 | $-6.33 Million | +0.03% |
| 2012-12-31 | $-6.34 Million | -24.21% |
| 2011-12-31 | $-5.10 Million | +6.73% |
| 2010-12-31 | $-5.47 Million | +4.45% |
| 2009-12-31 | $-5.72 Million | -55.54% |
| 2008-12-31 | $-3.68 Million | -325.91% |
| 2007-12-31 | $1.63 Million | +735.38% |
| 2006-12-31 | $195.00K | -94.49% |
| 2005-12-31 | $3.54 Million | -38.96% |
| 2004-12-31 | $5.80 Million | +566.21% |
| 2003-12-31 | $870.00K | -28.57% |
| 2002-12-31 | $1.22 Million | +128.52% |
| 2001-12-31 | $533.00K | -86.91% |
| 2000-12-31 | $4.07 Million | +51.47% |
| 1999-12-31 | $2.69 Million | -62.65% |
| 1998-12-31 | $7.20 Million | +5.88% |
| 1997-12-31 | $6.80 Million | +51.11% |
| 1996-12-31 | $4.50 Million | +4.65% |
| 1995-12-31 | $4.30 Million | -35.82% |
| 1994-12-31 | $6.70 Million | +139.29% |
| 1993-12-31 | $2.80 Million | -34.88% |
| 1992-12-31 | $4.30 Million | -6.52% |
| 1991-12-31 | $4.60 Million | -4.17% |
| 1990-12-31 | $4.80 Million | +23.08% |
| 1989-12-31 | $3.90 Million | +21.88% |
| 1988-12-31 | $3.20 Million | +3.23% |
| 1987-12-31 | $3.10 Million | +10.71% |
| 1986-12-31 | $2.80 Million | -9.68% |
| 1985-12-31 | $3.10 Million | -11.43% |
| 1984-12-31 | $3.50 Million | +12.90% |
| 1983-12-31 | $3.10 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to GT Biopharma Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 71160100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $26.00K | 0.45% |
| Other Components | $729.66 Million | 12608.64% |
| Total Equity | $5.79 Million | 100.00% |
GT Biopharma Inc Competitors by Market Cap
The table below lists competitors of GT Biopharma Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Niobay Metals Inc
V:NBY
|
$10.83 Million |
|
DCI O.N.
F:DCIK
|
$10.83 Million |
|
Talisman Mining Ltd
F:RJA
|
$10.83 Million |
|
Cosmos Health Inc.
NASDAQ:COSM
|
$10.83 Million |
|
Quantum Software SA
WAR:QNT
|
$10.82 Million |
|
Lithium Plus Minerals Ltd
AU:LPM
|
$10.81 Million |
|
i2S SA
PA:ALI2S
|
$10.81 Million |
|
Kalo Gold Corp
V:KALO
|
$10.80 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GT Biopharma Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -1,670,000 to 5,787,000, a change of 7,457,000.
- Net loss of 28,354,000 reduced equity.
- Dividend payments of 229,000 reduced retained earnings.
- New share issuances of 10,508,000 increased equity.
- Other factors increased equity by 25,532,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-28.35 Million | -489.96% |
| Dividends Paid | $229.00K | -3.96% |
| Share Issuances | $10.51 Million | +181.58% |
| Other Changes | $25.53 Million | +441.2% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares GT Biopharma Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.33x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 3.50x to 0.33x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1983-12-31 | $0.10 | $0.34 | x |
| 1984-12-31 | $0.11 | $0.34 | x |
| 1985-12-31 | $238461.54 | $0.34 | x |
| 1986-12-31 | $215384.62 | $0.34 | x |
| 1987-12-31 | $238461.54 | $0.34 | x |
| 1988-12-31 | $246153.85 | $0.34 | x |
| 1989-12-31 | $300000.00 | $0.34 | x |
| 1990-12-31 | $369230.77 | $0.34 | x |
| 1991-12-31 | $511111.11 | $0.34 | x |
| 1992-12-31 | $477777.78 | $0.34 | x |
| 1993-12-31 | $311111.11 | $0.34 | x |
| 1994-12-31 | $6700000.00 | $0.34 | x |
| 1995-12-31 | $477777.78 | $0.34 | x |
| 1996-12-31 | $642857.14 | $0.34 | x |
| 1997-12-31 | $1700000.00 | $0.34 | x |
| 1998-12-31 | $1200000.00 | $0.34 | x |
| 1999-12-31 | $448166.67 | $0.34 | x |
| 2000-12-31 | $581857.14 | $0.34 | x |
| 2001-12-31 | $76142.86 | $0.34 | x |
| 2002-12-31 | $174000.00 | $0.34 | x |
| 2003-12-31 | $43500.00 | $0.34 | x |
| 2004-12-31 | $0.00 | $0.34 | x |
| 2005-12-31 | $88909.09 | $0.34 | x |
| 2006-12-31 | $-16911.76 | $0.34 | x |
| 2007-12-31 | $21194.44 | $0.34 | x |
| 2008-12-31 | $-102222.22 | $0.34 | x |
| 2009-12-31 | $-159000.00 | $0.34 | x |
| 2010-12-31 | $-1823000.00 | $0.34 | x |
| 2011-12-31 | $-24175.36 | $0.34 | x |
| 2012-12-31 | $-16163.27 | $0.34 | x |
| 2013-12-31 | $-838.50 | $0.34 | x |
| 2014-12-31 | $-63372.84 | $0.34 | x |
| 2015-12-31 | $-3360000.00 | $0.34 | x |
| 2016-12-31 | $-117468.37 | $0.34 | x |
| 2017-12-31 | $255.33 | $0.34 | x |
| 2018-12-31 | $3.90 | $0.34 | x |
| 2019-12-31 | $-5.65 | $0.34 | x |
| 2020-12-31 | $-6.67 | $0.34 | x |
| 2021-12-31 | $0.78 | $0.34 | x |
| 2022-12-31 | $0.37 | $0.34 | x |
| 2023-12-31 | $5.55 | $0.34 | x |
| 2024-12-31 | $-0.88 | $0.34 | x |
| 2025-12-31 | $1.05 | $0.34 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently GT Biopharma Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -489.96%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.40x
- Recent ROE (-489.96%) is below the historical average (-119.68%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1983 | 5.00% | 3.92% | 1.09x | 1.17x | $-150.00K |
| 1984 | 12.00% | 10.10% | 1.09x | 1.09x | $70.00K |
| 1985 | -9.68% | -12.50% | 0.75x | 1.03x | $-610.00K |
| 1986 | -14.29% | -13.33% | 0.91x | 1.18x | $-680.00K |
| 1987 | 9.68% | 13.04% | 0.70x | 1.06x | $-10.00K |
| 1988 | 3.13% | 3.13% | 0.91x | 1.09x | $-220.00K |
| 1989 | 17.95% | 13.73% | 1.16x | 1.13x | $310.00K |
| 1990 | 18.75% | 18.75% | 0.96x | 1.04x | $420.00K |
| 1991 | -4.35% | -7.41% | 0.56x | 1.04x | $-660.00K |
| 1992 | -6.98% | -10.71% | 0.57x | 1.14x | $-730.00K |
| 1993 | -53.57% | -50.00% | 0.97x | 1.11x | $-1.78 Million |
| 1994 | -83.58% | -160.00% | 0.31x | 1.67x | $-6.27 Million |
| 1995 | -206.98% | -174.51% | 0.52x | 2.30x | $-9.33 Million |
| 1996 | -133.33% | -125.00% | 0.60x | 1.78x | $-6.45 Million |
| 1997 | -76.47% | -101.96% | 0.40x | 1.85x | $-5.88 Million |
| 1998 | -98.61% | -139.22% | 0.46x | 1.56x | $-7.82 Million |
| 1999 | -167.16% | -62.74% | 1.38x | 1.93x | $-4.76 Million |
| 2000 | -115.00% | -132.32% | 0.63x | 1.38x | $-5.09 Million |
| 2001 | -655.72% | -117.76% | 1.72x | 3.23x | $-3.55 Million |
| 2002 | -67.49% | -40.10% | 1.03x | 1.63x | $-943.80K |
| 2003 | -90.92% | -28.87% | 1.40x | 2.26x | $-878.00K |
| 2004 | -46.55% | -114.13% | 0.28x | 1.46x | $-3.28 Million |
| 2005 | -105.96% | -124.51% | 0.32x | 2.66x | $-3.40 Million |
| 2006 | 0.00% | -85.53% | 0.72x | 0.00x | $-4.88 Million |
| 2007 | 61.73% | 7.79% | 1.25x | 6.37x | $394.70K |
| 2008 | 0.00% | -437.97% | 1.94x | 0.00x | $-4.64 Million |
| 2009 | 0.00% | -4679.17% | 0.03x | 0.00x | $-1.67 Million |
| 2010 | 0.00% | -27227.27% | 0.06x | 0.00x | $-2.45 Million |
| 2011 | 0.00% | -14230.77% | 0.20x | 0.00x | $-3.19 Million |
| 2012 | 0.00% | -1511.99% | 1.51x | 0.00x | $-4.54 Million |
| 2013 | 0.00% | -136.14% | 2.50x | 0.00x | $132.40K |
| 2014 | 0.00% | -38506.56% | 0.07x | 0.00x | $-20.55 Million |
| 2015 | 0.00% | -79485.19% | 0.50x | 0.00x | $-16.42 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $11.64 Million |
| 2017 | -57.24% | -533970.37% | 0.00x | 1.01x | $-169.36 Million |
| 2018 | -2246.17% | 0.00% | 0.00x | 2.20x | $-260.34 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-36.73 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-25.37 Million |
| 2021 | -264.78% | 0.00% | 0.00x | 1.47x | $-60.20 Million |
| 2022 | -177.98% | 0.00% | 0.00x | 1.43x | $-22.06 Million |
| 2023 | -101.62% | 0.00% | 0.00x | 1.89x | $-8.34 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.99 Million |
| 2025 | -489.96% | 0.00% | 0.00x | 1.40x | $-28.93 Million |
Industry Comparison
This section compares GT Biopharma Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GT Biopharma Inc (GTBP) | $5.79 Million | 5.00% | 0.40x | $10.82 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About GT Biopharma Inc
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, tha… Read more